Physician profile
Michael Tzeng
NPI 1972032415
$3,066.42
in general payments reported to CMS, 2019-2025
22 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $239 · 2021: $468 · 2022: $699 · 2023: $530 · 2024: $739 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $679.91 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.87 | 2020-2025 | Lifevest |
| Philips North America LLC | $292.78 | 2024-2025 | (5044) Mcot, Extended Holter, Mcot |
| Astrazeneca Pharmaceuticals LP | $283.80 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $200.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $191.58 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $128.61 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $118.81 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $118.38 | 2020-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $113.18 | 2023-2025 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $111.92 | 2023-2024 | Verquvo |
| Preventice Services, LLC | $110.64 | 2020 | |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.52 | 2023-2025 | Jardiance |
| Amgen INC. | $45.09 | 2024-2025 | Repatha, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $42.23 | 2025 | Spaceoar Vue System - 10ml |
| Kiniksa Pharmaceuticals, LTD. | $30.27 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $27.94 | 2023-2025 | Camzyos |
| Cvrx, INC. | $20.95 | 2025 | Barostim Neo System |
| Mannkind Corporation | $19.79 | 2023 | Afrezza |
| Lilly USA, LLC | $17.31 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $14.66 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tzeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.